Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer

Gallbladder cancers (GBCs) together with intrahepatic and extrahepatic cholangiocarcinomas (CCAs) constitute rare malignancies of the biliary tract.1 Although all biliary tract cancers (BTCs) are associated with dismal outcome, GBC is the most common and aggressive, with an estimated incidence of 2.5 per 100,000 individuals worldwide and a 5-year overall survival (OS) rate of less than 5%.2,3 According to the GLOBOCAN 2018 data, GBC accounts for 1.2% of all diagnosed cancers, but 1.7% of all cancer-related deaths.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research